YU20050413A - Controlled release oxycodone compositions - Google Patents

Controlled release oxycodone compositions

Info

Publication number
YU20050413A
YU20050413A YU20050413A YU41305A YU20050413A YU 20050413 A YU20050413 A YU 20050413A YU 20050413 A YU20050413 A YU 20050413A YU 41305 A YU41305 A YU 41305A YU 20050413 A YU20050413 A YU 20050413A
Authority
YU
Yugoslavia
Prior art keywords
dosage form
controlled release
hours
oxycodone
oxycodone released
Prior art date
Application number
YU20050413A
Other languages
Serbo-Croatian (sh)
Inventor
Benjamin Oshlack
Mark Chasin
John Joseph Minogue
Robert Francis Kaiko
Original Assignee
Euro-Celtique S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro-Celtique S.A. filed Critical Euro-Celtique S.A.
Publication of YU20050413A publication Critical patent/YU20050413A/en
Publication of RS50058B publication Critical patent/RS50058B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Invention herewith described relates to a solid, controlled release, oral dosage form, the dosage form comprising an analgesically effective amount of oxycodone or a salt thereof in a matrix wherein the dissolution rate in vitro of the dosage form, when measured by the USP Paddle Method at 100 rpm at 900 ml aqueous buffer (pH between 1.6 and 7.2) at 37 DEG C. is between 12.5% and 42.5% (by wt) oxycodone released after 1 hour, between 25% and 55% (by wt) oxycodone released after 2 hours, between 45% and 75% (by wt) oxycodone released after 4 hours and between 55% and 85% (by wt) oxycodone released after 6 hours, the in vitro release rate being independent of pH between pH 1.6 and 7.2. Such a dosage form is achieved in the form of tablets. Invention also relates to such an oral dosage form preparation procedure.
YUP-2005/0413A 1992-11-25 1993-05-21 OXYCODON COMPOSITIONS WITH CONTROLLED RELEASE RS50058B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1014692A 1992-11-25 1992-11-25

Publications (2)

Publication Number Publication Date
YU20050413A true YU20050413A (en) 2006-08-17
RS50058B RS50058B (en) 2008-11-28

Family

ID=37616752

Country Status (2)

Country Link
ME (6) MEP47508A (en)
RS (2) RS50057B (en)

Also Published As

Publication number Publication date
RS50058B (en) 2008-11-28
MEP47508A (en) 2011-02-10
MEP48008A (en) 2011-02-10
MEP47608A (en) 2011-02-10
MEP47708A (en) 2011-02-10
RS50057B (en) 2008-11-28
MEP47908A (en) 2011-02-10
MEP47808A (en) 2011-02-10
YU20050411A (en) 2006-08-17

Similar Documents

Publication Publication Date Title
AU7407387A (en) Controlled release dihydrocodeine composition
GB2196848B (en) Controlled release hydromorphone composition
YU35893A (en) CONTROLLED-RELEASE OXIDON FORMULATIONS AND THEIR USE
CA2126611A1 (en) Opiod Formulations Having Extended Controlled Release
DE3783739D1 (en) Spheroiden.
RU2005115855A (en) COMPOSITION OF TRAMADOL PROLONGED BY RELEASE WITH 24 HOUR ACTION
PT1121109E (en) BIPHASIC FORMULATION CONTAINING TRAMADOL
YU20050413A (en) Controlled release oxycodone compositions
YU20050410A (en) Controlled release oxycodone compositions